Improved efficacy of fosmidomycin against plasmodium and mycobacterium species by combination with the cell-penetrating peptide octaarginine

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4689-4698

  Sparr, Christof ^a,b   Purkayastha, Nirupam ^a   Kolesinska, Beata ^a,c,d   Gengenbacher, Martin ^d   Amulic, Borko ^d   Matuschewski, Kai ^d   Seebach, Dieter ^a   Kamena, Faustin ^d  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^d MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (N ACETYL N HYDROXYAMINO)PROPYLPHOSPHONIC ACID; 3 [ACETYL(HYDROXY)AMINO]PROPHYLPHOSPHONIC ACID; ANTIMALARIAL AGENT; CELL PENETRATING PEPTIDE; FOSMIDOMYCIN; ISOPRENOID; OCTAARGININE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; APICOMPLEXA; ARTICLE; BACTERIAL STRAIN; BIOSYNTHESIS; BLOOD; CELL MEMBRANE PERMEABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INHIBITION; EXTRACELLULAR MATRIX; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR BACTERIUM; LIVER; MYCOBACTERIUM; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TOXOPLASMA GONDII;

ANTI-BACTERIAL AGENTS; ANTIMALARIALS; CELL-PENETRATING PEPTIDES; DRUG SYNERGISM; FOSFOMYCIN; MYCOBACTERIUM; OLIGOPEPTIDES; PLASMODIUM; TOXOPLASMA;

EID: 84884243908     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00427-13     Document Type: Article

References (47)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217.
2. World Health Organization. 2012. Global tuberculosis report. WHO, Geneva, Switzerland.
3. Vannice KS, Brown GV, Akanmori BD, Moorthy VS. 2012. MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines. Malar. J. 9:372.
4. Kaufmann SHE, Gengenbacher M. 2012. Recombinant live vaccine candidates against tuberculosis. Curr. Opin. Biotechnol. 23:900-907.
5. Hyde JE. 2007. Drug-resistant malaria-an insight. FEBS J. 274:4688- 4698.
6. Gengenbacher M, Kaufmann SHE. 2012. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol. Rev. 36:514-532.
7. Langel U. 2002. Cell-penetrating peptides. Processes and application. CRC Press, Boca Raton, FL.
8. Pujals S, Fernández-Carneado J, López-Iglesias C, Bogan MJ, Giralt E. 2006. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. BBA Biomembr. 1758:264-279.
9. Lindgren M, Hällbrink M, Prochiantz A, Langel U. 2000. Cellpenetrating peptides. Trends Pharmacol. Sci. 21:99-103.
10. Kamena F, Monnanda B, Makou D, Capone S, Patora-Komisarska Seebach KD. 2011. On the mechanism of eukaryotic-cell penetration of and oligoarginines: targeting infected erythrocytes. Chem. Biodivers. 8:1.
11. Jomaa H, Wiesner J, Sandenbrand S, Altincicek B, Weidemeyer C, Hintz M, Türbachova I, Eberl M, Zeidler J, Lichtenhalder HK, Soldati D, Beck E. 1999. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285:1573-1576.
12. Wanka M, Skorupinska-Tudek K, Swiezewska E. 2001. Isoprenoid biosynthesis via 1-deoxy-D-xylulose 5-phosphate/2-C-methyl-Derythritol 4-phosphate (DOXP/MEP) pathway. Acta Biochim. Pol. 48: 663- 672.
13. Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, Matsiegui PB, Binder R, Lell B, Wiesner J, Baranek T, Jomaa H, Kremsner PG. 2002. Fosmidomycin for malaria. Lancet 360:1941- 1942.
14. Wiesner J, Borrmann S, Jomaa H. 2003. Fosmidomycin for the treatment of malaria. Parasitol. Res. 90:71-76.
15. Borrmann S, Adegnika AA, Matsiegui PB, Issifou S, Schindler A, Mawili-Mboumba DP, Baranek T, Wiesner J, Jomaa H, Kremsner PG. 2004. Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children. J. Infect. Dis. 189:901-908.
16. Borrmann S, Issifou S, Esser G, Adegnika AA, Ramharter M, Matsiegui PB, Oyakhirome S, Mawili-Mboumba DP, Missinou MA, Kun JF, Jomaa H, Kremsner PG. 2004. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J. Infect. Dis. 190:1534 -1540.
17. Borrmann S, Adegnika AA, Moussavou F, Oyakhirome S, Esser G, Matsiegui PB, Ramharter M, Lundgren I, Kombila M, Issifou S, Hutchinson D, Wiesner J, Jomaa H, Kremsner PG. 2005. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 49:3749-3754.
18. Borrmann S, Lundgren I, Oyakhirome S, Impouma B, Matsiegui PB, Adegnika AA, Issifou S, Kun JF, Hutchinson D, Wiesner J, Jomaa H, Kremsner PG. 2006. Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 50:2713-2718.
19. Yeh E, Derisi JL. 2011. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol. 9:e1001138. doi:10.1371/journal.pbio.1001138.
20. Brown AC, Parish T. 2008. DRX is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to lack of uptake. BMC Microbiol. 8:78. doi:10.1186/1471-2180-8-78.
21. Nair SC, Brooks CF, Goodman CD, Sturm A, McFadden GI, Sundriyal S, Anglin JL, Song Y, Moreno SN, Striepen B. 2011. Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii. J. Exp. Med. 208:1547-1549.
22. Baumeister S, Wiesner J, Reichenberg A, Hintz M, Bietz S, Harb OS, Roos DS, Kordes M, Friesen J, Matuschewski K, Lingelbach K, Jomaa H, Seeber F. 2011. Fosmidomycin uptake into Plasmodiumand Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways. PLoS One 6:e19334. doi:10.1371/journal .pone.0019334.
23. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA. 2000. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6:1253-1257.
24. Samuel BU, Hearn B, Mack D, Wender P, Rothbard J, Kirisits MJ, Mui E, Wernimont S, Roberts CW, Muench SP, Rice DW, Prigge ST, Law AB, McLeod R. 2003. Delivery of antimicrobials into parasites. Proc. Natl. Acad. Sci. U. S. A. 100:14281-14286.
25. Goun EA, Pillow TH, Jones LR, Rothbard JB, Wender PA. 2006. Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. ChemBioChem 7:1497-1515.
26. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH. 2008. The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug Deliv. Rev. 60:452-472.
27. Wender PA, Verma VA, Paxton TJ, Pillow TH. 2008. Function-oriented synthesis, step economy, and drug design. Acc. Chem. Res. 41:40-49.
28. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA. 2008. Overcoming resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc. Natl. Acad. Sci. U. S. A. 105:12128-12133.
29. Wittenhagen LM, Carreon JR, Prestwich EG, Kelley SO. 2005. Phototoxicity of peptidoconjugates modulated by a single amino acid. Angew. Chem. 117:2598-2602.
30. Tünnemann G, Ter-avetisyan G, Martin RM, Stockl M, Hermann A, Cardoso C. 2008. Live-cell imaging of cell penetration ability and toxicity of oligoarginines. J. Pept. Sci. 14:469-476.
31. Umezawa N, Gelman MA, Haigis MC, Raines RT, Gellman SH. 2002. Translocation of a b-peptide across cell membranes. J. Am. Chem. Soc. 124:368-369.
32. Rueping M, Mahajan YR, Sauer M, Seebach D. 2002. Cellular uptake studies with b-peptides. ChemBioChem 3:257-259.
33. Seebach D, Namamoto K, Mahajan JR, Bindschädler P, Sustmann R, Kirsch M, Ryder NS, Weiss M, Sauer M, Roth C, Werner S, Beer HD, Munding C, Walde P, Voser M. 2004. Chemical and biological investigations of oligoarginines. Chem. Biodivers. 1:65-97.
34. Geueke B, Namamoto K, Agarkova I, Perriard JC, Kohler HP, Seebach D. 2005. Bacterial cell penetration by 3-oligoarginines: indication for passive transfer through the lipid bilayer. ChemBioChem 6:982-985.
35. Weiss HM, Wirz B, Schweitzer A, Amstutz R, Rodriguez-Perez MI, Andres H, Metz Y, Gardiner J, Seebach D. 2007. ADME investigations of unnatural peptides: distribution of a 14C-labeled 3-octaarginine in rats. Chem. Biodivers. 4:1413-1437.
36. Seebach D, Gardiner J. 2008. Peptidic peptidomimetics. Acc. Chem. Res. 41:1366-1375.
37. Nishihara M, Perret F, Takeuchi T, Futaki S, Lazar AN, Coleman AW, Sakai N, Matile S. 2005. Arginine magic with new counterions up the sleeve. Org. Biomol. Chem. 3:1569-1669.
38. Montenegro J, Gehin C, Bang EK, Fin A, Doval DA, Riezman H, Sakai N, Matile S. 2011. Conceptually new entries into cells. Chimia (Aarau) 65:853-858.
39. Arrighi RB, Ebikeme C, Jiang Y, Ranford-Cartwright L, Barrett MP, Langel U, Faye I. 2008. Cell-penetrating peptide TP10 shows broadspectrum activity against both Plasmodium falciparum and Trypanosoma brucei brucei. Antimicrob. Agents Chemother. 52:3414 -3417.
40. Haussig JM, Matuschweski K, Kooij TWA. 2013. Experimental genetics of Plasmodium berghei NFU in the apicoplast iron-sulfur cluster biogenesis pathways. PLoS One 8:e67269. doi:10.1371/journal.pone.0067269.
41. Dhiman RK, Schaeffer ML, Bailey AM, Testa CA, Scherman H, Crick DC. 2005. 1-Deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacterial resistance to fosmidomycin. J. Bacteriol. 187:8395-8402.
42. Schwab JC, Beckers CJ, Joiner KA. 1994. The parasitophorous vacuole membrane surrounding intracellular Toxoplasma gondii functions as a molecular sieve. Proc. Natl. Acad. Sci. U. S. A. 18:509-513.
43. Desai SA, Krogstad DJ, McCleskey EW. 1993. A nutrient-permeable channel on the intraerythrocytic malaria parasite. Nature 362:643- 646.
44. Desai SA, Rosenberg RL. 1997. Pore size of the malaria parasite's nutrient channel. Proc. Natl. Acad. Sci. U. S. A. 94:2045-2049.
45. Spielmann T, Montagna GN, Hecht L, Matuschweski K. 2012. Molecular make-up of the Plasmodium parasitophorous vacuolar membrane. Int. J. Med. Microbiol. 302:179-186.
46. Sarathy J, Dartois V, Dick T, Gengenbacher M. 2013. Reduced drug uptake in phenotypically resistant nutrient-starved non-replicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:1648 - 1653.
47. Kamei N, Morishita M, Takayama K. 2009. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/ protein absorption using cell-penetrating peptides. J. Control Release 136: 179-186.